This Article Full Text (PDF) All Versions of this Article: 0269881106070996v1 21/4/421    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lee, B.-J. Articles by Kim, Y.-H. Search for Related Content PubMed PubMed Citation Articles by Lee, B.-J. Articles by Kim, Y.-H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB HALOPERIDOL Medline Plus Health Information Schizophrenia Social Bookmarking                         What's this?

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia

Department of Psychiatry, School of Medicine and Paik Institute for Clinical Research, Inje University, Republic of Korea

Jung-Goo Lee

Department of Psychiatry, Dong Suh Mental Hospital, Masan, South Korea.

Young-Hoon Kim

Department of Psychiatry, School of Medicine and Paik Institute for Clinical Research, Inje University, Republic of Korea, npkyh{at}chol.com

To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments.

Twenty-four subjects stabilized on haloperidol treatment (5—30 mg/day) for a minimum of 3 months were entered into a double-blind, placebo-controlled trial of donepezil as an adjunctive treatment. Subjects were randomly assigned under doubLe-blind conditions to receive either 5 mg/day donepezil (N = 12) or pLacebo (N = 12) for 12 weeks. The subjects were evaluated at baseline, and after 4, 8, and 12 weeks using the Korean version of Mini MentaL State Examination (K-MMSE), Brief Psychiatric Rating Scale (BPRS), and standard neuropsychological assessment.

The K-MMSE scores improved significantly (p < 0.05) but the BPRS scores did not improve significantly in patients given donepezil; subjects

showed slight improvement in several cognitive measures. At the end of the study, the difference in the mean K-MMSE scores between the donepezil and placebo groups approached statistical significance (p = 0.056). Of the several domains of cognitive functions assessed, verbaL recognition and visuaL recall memory improved significantly (p < 0.05). But donepezil did not affect scores in the executive function tests.

Our findings support a potential positive effect of AChEIs in the management of cognitive impairments in patients with chronic schizophrenia. Further studies with Large subjects are needed to confirm our findings.

Key Words: donepezil • cognition • schizophrenia

This version was published on June 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 4, 421-427 (2007)
DOI: 10.1177/0269881106070996


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?